STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Diamyd Medical (STO:DIAMB) (Pink Sheets:DMYDY) Substantial and sustained reduction in pain scores were reported in the middle and high dose cohorts of Diamyd Medical’s Phase I, open-label, dose escalation trial investigating NP2 Enkephalin as a potential therapy for chronic pain. No treatment related Serious Adverse Events have been observed in the study to date.
